5-APB
5-APB (abbreviation of "5-(2-aminopropyl)benzofuran"; see infobox for the correct IUPAC name) is an empathogenic psychoactive compound of the substituted benzofuran, substituted amphetamine and substituted phenethylamine classes. 5-APB and other compounds are sometimes informally called "Benzofury". 5-APB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 10% more potent by mass and doses should be adjusted accordingly. 5-APB has been sold as a designer drug since 2010. Pharmacology. 5-APB is a serotonin–norepinephrine–dopamine reuptake inhibitor with "K"(NET)=180 nmol/L, "K"(DAT)=265 nmol/L and "K"(SERT)=811 nmol/L. It is  also a serotonin–norepinephrine–dopamine releasing agent. 5-APB is a potent agonist for the 5-HT and 5-HT receptors (K of 14 nmol/L at 5-HT with an efficacy of 0.924). This agonism for 5-HT makes it likely that 5-APB would be cardiotoxic with long term use, as seen in other 5-HT agonists such as fenfluramine and MDMA. 5-APB is also an agonist of the 5-HT receptor. Detection. A forensic standard of 5-APB is available, and the compound has been posted on the Forendex website of potential drugs of abuse. The  US Department of Justice and DEA have also conducted studies concerning the detection of 5-APB. Effects. Users describe effects as euphoric. Largely, effects reported were similar to that of the drug MDMA but not as strong. Recreational use of 5-APB has been associated with death in combination with other drugs and solely as the result of 5-APB. According to investigative reporting by David Nickles and Lily Kay Ross, a coroner's report identified "complications of 5-APB and other substance abuse" as the cause of death of Jen Rothman, who had been introduced to 5-APB by  psychedelic practitioner Jorge Ferrer. The reporters state that the mechanism of death was likely to have been hyponatremia, caused by the increased action of serotonin induced by 5-APB. They note that telltale symptoms of hyponatremia, "Thirst, exhaustion, seizures, and vomiting [were] in Jen’s texts and the police report" pertaining to the incident. Such an effect has been documented for MDMA, which has a similar mechanism of action and subjective effects. Legality. On March 5, 2014 the UK Home Office announced that 5-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran  entactogen and many structurally related drugs.